Gut mRNA tech supercharges vaccine and GLP-1 delivery

Дата публикации: 01-10-2026 13:00:02

From vaccines to gene therapies, mRNA medicines often rely on tiny fat-based particles called lipid nanoparticles, or LNPs, to carry treatments where they need to go. But researchers still face a fundamental challenge: getting those therapies to the organs where they are needed most while limiting side effects elsewhere in the body.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Automated lipid nanoparticle production could accelerate the development of RNA therapies	0	8.2	28-09-2026
2	Freezing threatens mRNA delivery, but Tris buffer helps nanoparticles retain their potency	0	7	25-09-2026
3	Год на полке: мРНК-вакцина пережила комнатную температуру	0	16.25	29-09-2026
4	A ‘living GLP-1 drug’ could revolutionize diabetes treatment	0	12.36	20-08-2026
5	STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more	0	6.55	28-09-2026
6	A GLP-1 has changed your life. Are you stuck taking it forever?	0	7.16	05-09-2026
7	GLP-1s Could Change More Than Your Appetite: What We Know About Their Impact on ADHD, Brain Health and Libido	0	6.29	14-09-2026
8	STAT+: Once described as obesity medicines for ‘patients,’ GLP-1s are increasingly lifestyle drugs for ‘customers’	0	7.79	28-09-2026
9	Engineered nanoparticles sensitize gliomas to radiotherapy	0	9.54	21-09-2026
10	Российские ученые назвали фаворитов Нобелевской премии	0	11.66	04-10-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 8.96. Источник: phys.org.